KAITLAN GRIFFITH: Open Payments
NPI 1629534870 · ST PETERSBURG, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$377 in 16 payments from 13 companies in 2025. Trend: 2023 $2,063 · 2024 $2,204 · 2025 $377
Food & beverage: $377
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $63 |
| ABBVIE INC. | 2 | $56 |
| Vanda Pharmaceuticals Inc. | 1 | $36 |
| Axsome Therapeutics, Inc. | 1 | $32 |
| Supernus Pharmaceuticals, Inc. | 1 | $25 |
| Janssen Pharmaceuticals, Inc | 1 | $23 |
| Almatica Pharma LLC | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| Alkermes, Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $21 |
Products named: INGREZZA, VRAYLAR, HETLIOZ, Auvelity, Qelbree, SPRAVATO, LOREEV XR, CAPLYTA.
Industry payments across FL — which companies pay providers there.
